{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:01:03Z","timestamp":1792166463101,"version":"4.4.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novo Nordisk A\/S"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Fibroblast growth factor 21 (FGF21) analogs have significant therapeutic potential in metabolic dysfunction\u2013associated steatohepatitis (MASH) but limited body weight effects in patients with MASH. This study investigated the effect of combined treatment with the FGF21 analog zalfermin and the glucagon-like peptide-1 receptor agonist semaglutide on body weight\u00a0and plasma and liver biochemistry and histology in a mouse model of MASH. Amylin liver nonalcoholic steatohepatitis diet-induced obese-MASH mice with biopsy-confirmed MASH and fibrosis were administered (subcutaneous [SC], daily [QD]) vehicle, zalfermin (0.05 or 0.2\u2009mg\/kg), semaglutide (3 or 120 \u00b5g\/kg), or zalfermin 0.05\u2009mg\/kg\u2009+\u2009semaglutide 3 \u00b5g\/kg for 8 weeks (n\u2009=\u200911\u201312 per group). Vehicle-dosed (SC, QD) chow-fed mice served as normal controls (n\u2009=\u200910). Pre- to post-liver biopsy histology was compared for within-subject evaluation of changes in non-alcoholic fatty liver disease Activity Score (NAS), fibrosis stage, and quantitative histology. Additional endpoints included plasma\/liver biochemistry and liver RNA sequencing. Combined low-dose zalfermin and semaglutide treatment resulted in super-additive body weight loss (\u221218%) vs. individual low-dose monotherapies (zalfermin, \u22126%; semaglutide, \u22124%) and was equally effective as high-dose zalfermin monotherapy (\u221216%) and semaglutide (\u221215%). Low-dose combination therapy promoted greater benefits on transaminases, total cholesterol and triglycerides, NAS, steatosis, and inflammation vs. individual low-dose monotherapies and high-dose semaglutide, and high-dose zalfermin was as effective as the low-dose combination therapy on most endpoints. Combination treatment reduced gene expression markers of fibrosis to a greater degree than monotherapies. In conclusion, combined low-dose zalfermin and semaglutide, as well as high-dose zalfermin, resulted in beneficial effects on body weight and biochemical and histological endpoints, supporting the clinical development of zalfermin as therapy for patients with MASH.<\/jats:p>","DOI":"10.1371\/journal.pone.0331665","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:24:11Z","timestamp":1761672251000},"page":"e0331665","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH"],"prefix":"10.1371","volume":"20","author":[{"given":"Jenny","family":"Norlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6287-8367","authenticated-orcid":true,"given":"Maria","family":"Dermit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth D.","family":"Galsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik H.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Feigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne S.","family":"Veidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Latta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1423-6797","authenticated-orcid":true,"given":"Birgitte","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"1","key":"pone.0331665.ref001","doi-asserted-by":"crossref","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"ME Rinella","year":"2024","journal-title":"Ann Hepatol"},{"issue":"6","key":"pone.0331665.ref002","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"DE Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"10","key":"pone.0331665.ref003","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41575-023-00796-x","article-title":"Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach","volume":"20","author":"PN Brennan","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pone.0331665.ref004","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the Physiology of FGF21","volume":"78","author":"FM Fisher","year":"2016","journal-title":"Annu Rev Physiol"},{"issue":"4","key":"pone.0331665.ref005","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/me.2007-0313","article-title":"betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c","volume":"22","author":"M Suzuki","year":"2008","journal-title":"Mol Endocrinol"},{"issue":"6","key":"pone.0331665.ref006","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41366-018-0080-7","article-title":"FGF21 decreases body weight without reducing food intake or bone mineral density in high-fat fed obese rhesus macaque monkeys","volume":"42","author":"B Andersen","year":"2018","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"pone.0331665.ref007","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic Messengers: FGF21","volume":"3","author":"KH Flippo","year":"2021","journal-title":"Nat Metab"},{"issue":"12","key":"pone.0331665.ref008","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"SA Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"pone.0331665.ref009","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"R Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0331665.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study","volume":"22","author":"R Loomba","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"pone.0331665.ref011","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgab624","article-title":"LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia","volume":"107","author":"DJ Rader","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0331665.ref012","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/TCRM.S352008","article-title":"Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease","volume":"19","author":"DD Raptis","year":"2023","journal-title":"Ther Clin Risk Manag"},{"issue":"14","key":"pone.0331665.ref013","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acs.jmedchem.4c00391","article-title":"Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog","volume":"67","author":"K Sass-\u00d8rum","year":"2024","journal-title":"J Med Chem"},{"key":"pone.0331665.ref014","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"MA Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"pone.0331665.ref015","unstructured":"FDA. WEGOVY prescribing information. 2021 [cited 2025 Jan 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215256s000lbl.pdf"},{"issue":"12","key":"pone.0331665.ref016","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"PN Newsome","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0331665.ref017","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tem.2024.02.001","article-title":"Current status and future perspectives of FGF21 analogues in clinical trials","volume":"35","author":"ZSW Chui","year":"2024","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"pone.0331665.ref018","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","article-title":"Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH\/MASH and Type 2 Diabetes in a Randomized Phase 2 Study","volume":"23","author":"SA Harrison","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"pone.0331665.ref019","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00079.2013","article-title":"Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment","volume":"305","author":"JR Clapper","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"pone.0331665.ref020","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"M Vacca","year":"2024","journal-title":"Nat Metab"},{"issue":"16","key":"pone.0331665.ref021","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4254\/wjh.v8.i16.673","article-title":"Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy","volume":"8","author":"MNB Kristiansen","year":"2016","journal-title":"World J Hepatol"},{"key":"pone.0331665.ref022","unstructured":"FDA. Tertiary pharmacology\/toxicology review and evaluation of semaglutide. 2016 [cited 2025 Jan 21]."},{"key":"pone.0331665.ref023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2017.03.020","article-title":"Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species","volume":"104","author":"L Jensen","year":"2017","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"pone.0331665.ref024","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/cts.13235","article-title":"Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH","volume":"15","author":"MB M\u00f8llerh\u00f8j","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"1","key":"pone.0331665.ref025","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12876-020-01356-2","article-title":"Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis","volume":"20","author":"HH Hansen","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"pone.0331665.ref026","doi-asserted-by":"crossref","first-page":"101850","DOI":"10.1016\/j.molmet.2023.101850","article-title":"Evaluation of long acting GLP1R\/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1\/glucagon agonism in NASH patients","volume":"79","author":"T Monfeuga","year":"2024","journal-title":"Mol Metab"},{"issue":"33","key":"pone.0331665.ref027","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.3748\/wjg.v25.i33.4904","article-title":"Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source","volume":"25","author":"ML Boland","year":"2019","journal-title":"World J Gastroenterol"},{"key":"pone.0331665.ref028","doi-asserted-by":"crossref","first-page":"601349","DOI":"10.3389\/fendo.2020.601349","article-title":"FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human","volume":"11","author":"E Henriksson","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"pone.0331665.ref029","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00157.2022","article-title":"Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis","volume":"324","author":"MH Nielsen","year":"2023","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"21","key":"pone.0331665.ref030","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","year":"2025","journal-title":"N\u00a0Engl J\u00a0Med"},{"issue":"1","key":"pone.0331665.ref031","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study","volume":"22","author":"MF Abdelmalek","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"pone.0331665.ref032","doi-asserted-by":"crossref","first-page":"100057","DOI":"10.1016\/j.xcrm.2020.100057","article-title":"AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients","volume":"1","author":"A Kaufman","year":"2020","journal-title":"Cell Rep Med"},{"issue":"3","key":"pone.0331665.ref033","article-title":"FGF21 and the Physiological Regulation of Macronutrient Preference","volume":"161","author":"CM Hill","year":"2020","journal-title":"Endocrinology"},{"issue":"6","key":"pone.0331665.ref034","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3945\/ajcn.112.044321","article-title":"Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials","volume":"96","author":"TP Wycherley","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"pone.0331665.ref035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11154-020-09574-5","article-title":"Protein, amino acids and obesity treatment","volume":"21","author":"M Simonson","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"pone.0331665.ref036","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"T Coskun","year":"2008","journal-title":"Endocrinology"},{"issue":"4","key":"pone.0331665.ref037","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cmet.2014.07.012","article-title":"FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss","volume":"20","author":"BM Owen","year":"2014","journal-title":"Cell Metab"},{"issue":"11","key":"pone.0331665.ref038","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"FM Fisher","year":"2010","journal-title":"Diabetes"},{"issue":"5","key":"pone.0331665.ref039","article-title":"Short-term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice","volume":"11","author":"JN Feng","year":"2023","journal-title":"Physiol Rep"},{"issue":"11","key":"pone.0331665.ref040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048392","article-title":"Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance","volume":"7","author":"M Yang","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"pone.0331665.ref041","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI67353","article-title":"Interplay between FGF21 and insulin action in the liver regulates metabolism","volume":"124","author":"B Emanuelli","year":"2014","journal-title":"J Clin Invest"},{"issue":"4","key":"pone.0331665.ref042","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"C Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"2","key":"pone.0331665.ref043","article-title":"Loss of SLC27A5 Activates Hepatic Stellate Cells and Promotes Liver Fibrosis via Unconjugated Cholic Acid","volume":"11","author":"K Wu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"pone.0331665.ref044","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/j.2040-4603.2013.tb00517.x","article-title":"Bile acid metabolism and signaling","volume":"3","author":"JYL Chiang","year":"2013","journal-title":"Compr Physiol"},{"key":"pone.0331665.ref045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-4614-0887-1_11","article-title":"Physiology of FGF15\/19","volume":"728","author":"SA Jones","year":"2012","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"pone.0331665.ref046","doi-asserted-by":"crossref","first-page":"100392","DOI":"10.1016\/j.jhepr.2021.100392","article-title":"Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis","volume":"4","author":"Y Luo","year":"2022","journal-title":"JHEP Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:24:19Z","timestamp":1761672259000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331665"}},"subtitle":[],"editor":[{"given":"Nobuyuki","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0331665","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]}}}